CHILDRENS CANCER GROUP

儿童癌症组

• 批准号: 6124401
• 负责人: FREDERICK B RUYMANN
• 金额: $ 19.89万
• 依托单位: RESEARCH INST NATIONWIDE CHILDREN'S HOSP
• 依托单位国家: 美国
• 财政年份: 1994
• 资助国家: 美国
• 起止时间: 1994-03-01 至 2002-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6124401
• 关键词: acute lymphocytic leukemia; acute myelogenous leukemia; antineoplastics; bone marrow transplantation; bone neoplasms; brain neoplasms; clinical research; clinical trials; combination cancer therapy; combination chemotherapy; cooperative study; cytogenetics; data management; human subject; human therapy evaluation; liver neoplasms; lymphoma; molecular oncology; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer epidemiology; neoplasm /cancer immunotherapy; neoplasm /cancer pharmacology; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neuroblastoma; oncology nursing; pediatric neoplasm /cancer; statistics /biometry; tissue resource /registry

Columbus Children's Hospital (CCH) is a 313-bed fully capable children's hospital, which has been a funded Childrens Cancer Group (CCG) institution since 1958. Dr. Frederick B. Ruymann has been the Principal Investigator (PI) and CCG representative to the Intergroup Rhabdomyosarcoma Study (IRS) since November 1982. The Division of Hematology/Oncology is the pediatric component of the OSU-NCI funded Comprehensive Cancer Center and has an approved hematology/oncology fellowship with 60 residents in pediatrics. CCH serves as the CCG-Pathology Center, which is under the direction of Dr. Stephen Qualman (Co-Investigator), a member of the CCG Pathology Steering Committee. The CCH/CCG Network, which includes three other institutions in Ohio, The Medical College of Ohio (Toledo), the Children's Medical Center/Wright Patterson AFB (Dayton), and The Cleveland Clinic Foundation (Cleveland), saw 241 children and adolescents with newly diagnosed malignancy in 1996. In November 1997, the Cabell Huntington Hospital in Huntington, West Virginia became the fourth affiliate in the CCH/CCG network. From 1992 through 1996 an average of 87 patients were placed annually on CCG therapeutic (Phase I/II) studies; 56 cases per year were placed on non-therapeutic studies. From 1992-1996, there were 437 therapeutic and 282 non-therapeutic CCG entries by the CCH/CCG Network. CCH/CCG Network follows 561 long-term survivors of childhood cancer and an additional 213 survivors on Intergroup studies. CCH is an approved CCG Phase I/II (1990) and bone marrow transplant (1992) institution under the direction of Drs. Kathryn Klopfenstein and Alfred Grovas (Co-Investigators), respectively. CCH was approved by the National Marrow Donor Program for the performance of matched unrelated transplants in July 1997. CCH's resident scientist, M. Sue O'Dorisio, MD, PhD (Co-Investigator) is a world expert on the neuropeptide regulation of neuroblastoma and a member of the CCG Neuroblastoma Strategy Committee. Other Co-Investigators on this grant include Dr. Allan Yates (neuropathology), and Dr. Amanda Rauck (pediatric oncology) who both have major roles in CCG science and leadership. CCH has made major contributions in diagnosis, treatment, and biology of leukemia, rhabdomyosarcoma, brain tumors, and neuroblastoma, through CCG pilot and pre-clinical investigations. Current protocols or proposals include escalating cyclophosphamide in intermediate risk rhabdomyosarcoma, neuropeptide imaging in neuroblastoma and peripheal neural ectodermal tumors, high-dose rate brachytherapy in soft tissue sarcomas, and bone marrow transplant in brain tumors. The status of each of these protocols is discussed in the text of this competing renewal.

哥伦布儿童医院（CCH）是一家313张床的能力完全有能力的儿童医院，自1958年以来一直是一家资助的儿童癌小组（CCG）机构。弗雷德里克·B·鲁曼（Frederick B. OSU-NCI资助了综合癌症中心，并拥有批准的血液学/肿瘤学研究金，其中60名儿科居民。 CCH是CCG病理学中心，该中心是CCG病理学指导委员会成员Stephen Qualman博士（共同投资者）的指导。 CCH/CCG网络包括俄亥俄州的其他三个机构，俄亥俄州的医学院（托莱多），儿童医疗中心/赖特·帕特森（Wright Patterson）AFB（代顿）和克利夫兰诊所基金会（克利夫兰）（克利夫兰），有241名儿童和青少年在1996年11月诊断出恶性肿瘤。 CCH/CCG网络。 从1992年到1996年，每年平均将87名患者接受CCG治疗（I/II期）研究。每年进行56例非治疗研究。 从1992- 1996年，CCH/CCG网络有437个治疗性和282个非治疗性CCG条目。 CCH/CCG网络遵循561个儿童癌症的长期幸存者，并在群体间研究中还有213个幸存者。 CCH是批准的CCG I/II期（1990）和骨髓移植（1992）在DRS的指导下进行的。 Kathryn Klopfenstein和Alfred Grovas（共同研究者）。 CCH在1997年7月获得了国家骨髓捐助计划，以表现出匹配的无关移植。 该赠款的其他共同投资者包括Allan Yates博士（神经病理学）和Amanda Rauck博士（儿科肿瘤学），他们在CCG科学和领导力中都起着重要作用。 CCH通过CCG试验和临床前研究在白血病，横纹肌肉瘤，脑瘤和神经母细胞瘤方面做出了重大贡献。 当前的方案或提案包括在中间风险的横纹肌肉瘤中升级环磷酰胺，神经母细胞瘤中的神经肽成像和外周神经外胚性肿瘤，软组织肉瘤中的高剂量hirtherpherapy和脑骨髓的骨髓移植。 这些协议中的每一个的状态都在此竞争更新的文本中讨论。